Search
for
Sort by
Research 751–780 of 1000+
- Management of the adverse effects of targeted therapy for cancer
- Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults
- Bridging Personal and Population in Excitability Diseases: Will Studies of Rare Diseases Bring Generalizable Mechanisms From Monogenic Channelopathies?
- Nitroglycerin in Dermatology
- Prepregnancy Phenotype and Physiological Characteristics in PCOS
- A MODERN VIEW OF THE POLYCYSTIC OVARIAN SYNDROME
- Skin Manifestations of Paediatric Metabolic Syndrome
- Association of common medication with prostate-specific antigen level in 45-year-old German men: Results of the PROBASE trial
- POLYCYSTIC OVARY SYNDROME (PCOS)–AN OVERVIEW
- Metabolic Syndrome – Myth or Reality in the Endocrinology Clinic
- Investigation of the crosstalk between proteasome function and nucleotide excision repair mechanism during ageing
- Fertility and Sterility Vol 101 No 4, April 2014
- Long-term consequences of critical illness
- The Pharma Market as Reflected by Patents
- EFECTO DE LA TESTOSTERONA, 4-HIDROXIANDROSTENDIONA Y FINASTERIDE SOBRE LA HEMOSTASIA EN UN MODELO DE ISQUEMIA/REPERFUSION CORONARIA EN RATA
- Reporting on Adverse Clinical Events
- Polycystic Ovary Syndrome and the Metabolic Syndrome Long-Term Risks
- Case presentation: Catastrophic decrease in measured oxygen saturation associated with venoveno bypass during liver transplantation
- News in brief ???
- Minoxidil.
- No increased risk of CV events with dutasteride vs finasteride
- Epidemiology, diagnosis, and management of polycystic ovary syndrome
- Polycystic ovary syndrome
- Stem Cells Applications in Regenerative Medicine and Disease Therapeutics
- The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
- BPH: epidemiology and comorbidities.
- The Rotterdam Study: 2016 objectives and design update
- Targeted Inactivation of Gh/Tissue Transglutaminase II
- Polycystic Ovary Syndrome